Isotype changes in and characteristics of patients with APBs (n = 4)
| ID . | Sex . | Age, y . | Primary monoclonal protein . | ASCT . | Last treatment line regimen . | Time from last line of treatment to CAR T-cell infusion, mo . | Clonal band pattern . | Time from infusion to onset of APBs, mo . | APB duration, mo . | Clinical response . | PFS, mo . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TJ02 | M | 73 | IgGλ | No | TD | 3 | IgGλ → IgGκ + IgGλ → IgGκ → normal | 3 | 9 | sCR | 25 |
| TJ09 | F | 51 | IgDλ | No | RCD | 6 | (IgD)λ → IgGλ → IgGκ + IgGλ → normal | 2 | 7 | sCR | 12 |
| TJ10 | M | 49 | IgGλ | No | VDEP | 3 | IgGλ→ oligo IgGκ + IgGλ → normal | 6 | 3 | sCR | 9 |
| TJ12 | M | 53 | κ light chain | No | VRD | 3 | κ → normal → IgGκ + oligo IgGλ → normal | 5 | 3 | sCR | 8 |
| ID . | Sex . | Age, y . | Primary monoclonal protein . | ASCT . | Last treatment line regimen . | Time from last line of treatment to CAR T-cell infusion, mo . | Clonal band pattern . | Time from infusion to onset of APBs, mo . | APB duration, mo . | Clinical response . | PFS, mo . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TJ02 | M | 73 | IgGλ | No | TD | 3 | IgGλ → IgGκ + IgGλ → IgGκ → normal | 3 | 9 | sCR | 25 |
| TJ09 | F | 51 | IgDλ | No | RCD | 6 | (IgD)λ → IgGλ → IgGκ + IgGλ → normal | 2 | 7 | sCR | 12 |
| TJ10 | M | 49 | IgGλ | No | VDEP | 3 | IgGλ→ oligo IgGκ + IgGλ → normal | 6 | 3 | sCR | 9 |
| TJ12 | M | 53 | κ light chain | No | VRD | 3 | κ → normal → IgGκ + oligo IgGλ → normal | 5 | 3 | sCR | 8 |
Ig, immunoglobulin; RCD, lenalidomide, cyclophosphamide, and dexamethasone; TD, thalidomide and dexamethasone; VDEP, bortezomib, dexamethasone, etoposide, and cisplatin; VRD, bortezomib, lenalidomide, and dexamethasone.